Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Kenai Therapeutics
United States
- San Diego, California
- 01/03/2024
- Series A
- $28,000,000
Kenai Therapeutics is a biotechnology company pioneering next generation approaches to cure neurological disorders. The Company utilizes allogeneic induced pluripotent stem cell (iPSC) technology, a Nobel Prize-winning breakthrough that enables scientists to manufacture many human cell types, in order to advance Kenai’s off-the-shelf neuron replacement therapeutics. By focusing on an iPSC technology platform, and forging partnerships with global leaders in surgical delivery and clinical development, Kenai is dedicated to advancing a best-in-class pipeline targeting neurological diseases.
- Industry Biotechnology Research
- Website https://www.kenaitx.com/
- LinkedIn https://www.linkedin.com/company/kenaitx/
Related People
Howard FederoffCo Founder
United States -
Miami, Florida
Experienced Senior Executive and CEO with a demonstrated history of working in the higher education and biotech industries. Skilled in leading complex organizations, philanthropy and driving excellence, academic and clinical by empowering great teams.
MD, PhD Albert Einstein College of Medicine
Board Certified Internal Medicine, Endocrinology and Metabolism
Expertise in gene therapy, biomarkers, systems medicine and advanced biologics for Parkinson's disease.
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)